Sierra-Sánchez, V.M.; Ocampo-Ortega, S.A.; Villafaña-Hernandez, S.; Jiménez, E.M.; Fonseca, R.A.R.; Aguilera-Méndez, A.; Romero-Nava, R.; Hong, E.; MacÃas-Pérez, M.E.; Villafaña, S.
Development of a Rationally Designed siRNA-Based Therapeutic Targeting PD-L1 in Triple-Negative Breast Cancer. Sci. Pharm. 2026, 94, 53.
https://doi.org/10.3390/scipharm94030053
AMA Style
Sierra-Sánchez VM, Ocampo-Ortega SA, Villafaña-Hernandez S, Jiménez EM, Fonseca RAR, Aguilera-Méndez A, Romero-Nava R, Hong E, MacÃas-Pérez ME, Villafaña S.
Development of a Rationally Designed siRNA-Based Therapeutic Targeting PD-L1 in Triple-Negative Breast Cancer. Scientia Pharmaceutica. 2026; 94(3):53.
https://doi.org/10.3390/scipharm94030053
Chicago/Turabian Style
Sierra-Sánchez, Vivany Maydel, Sergio Adrian Ocampo-Ortega, Santiago Villafaña-Hernandez, Elvia Mera Jiménez, Rolando Alberto RodrÃguez Fonseca, Asdrubal Aguilera-Méndez, Rodrigo Romero-Nava, Enrique Hong, Martha Edith MacÃas-Pérez, and Santiago Villafaña.
2026. "Development of a Rationally Designed siRNA-Based Therapeutic Targeting PD-L1 in Triple-Negative Breast Cancer" Scientia Pharmaceutica 94, no. 3: 53.
https://doi.org/10.3390/scipharm94030053
APA Style
Sierra-Sánchez, V. M., Ocampo-Ortega, S. A., Villafaña-Hernandez, S., Jiménez, E. M., Fonseca, R. A. R., Aguilera-Méndez, A., Romero-Nava, R., Hong, E., MacÃas-Pérez, M. E., & Villafaña, S.
(2026). Development of a Rationally Designed siRNA-Based Therapeutic Targeting PD-L1 in Triple-Negative Breast Cancer. Scientia Pharmaceutica, 94(3), 53.
https://doi.org/10.3390/scipharm94030053
